Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6217]

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

Defeating leukaemia cells by depriving them of energy

Defeating leukaemia cells by depriving them of energy

ecancer are launching a new initiative to improve cancer care in low-income countries with support from Bristol Myers Squibb

ecancer are launching a new initiative to improve cancer care in low-income countries with support from Bristol...

ASCO GU 2022: Olaparib plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer

ASCO GU 2022: Olaparib plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st...

With personalised medicine, a shelved cancer drug could get another shot

With personalised medicine, a shelved cancer drug could get another shot

The promise of PD-1 inhibition in relapsed cervical cancer

The promise of PD-1 inhibition in relapsed cervical cancer

Pivotal phase 3 data for pembrolizumab in high-risk early-stage triple-negative breast cancer (TNBC)

Pivotal phase 3 data for pembrolizumab in high-risk early-stage triple-negative breast cancer (TNBC)

Surgeons use cutting-edge technology to perform first ever non-invasive brain tumour surgery

Surgeons use cutting-edge technology to perform first ever non-invasive brain tumour surgery

Immune cells leave fingerprints on tumours metastasised to the brain offering clues to future therapies

Immune cells leave fingerprints on tumours metastasised to the brain offering clues to future therapies

Report details impact of COVID-19 on US cancer research and patient care

Report details impact of COVID-19 on US cancer research and patient care

More from ecancer